The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[3]Department of Urology, The Third People's Hospital of Chengdu, Chengdu, China.
National Natural Science Foundation of China,
Grant/Award Numbers: 81672547,
81872107, 81872108, 81972502, 81902577;
1.3.5 project for disciplines of excellence,
West China Hospital, Sichuan University,
Grant/Award Number: 0040205301E21
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|3 区医学
小类|3 区内分泌学与代谢3 区泌尿学与肾脏学
最新[2023]版：
大类|3 区医学
小类|3 区泌尿学与肾脏学4 区内分泌学与代谢
第一作者：
第一作者机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.[*1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China.
推荐引用方式(GB/T 7714)：
Wang Zhipeng,Zhu Sha,Zhao Jinge,et al.The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.[J].The Prostate.2021,doi:10.1002/pros.24215.
APA：
Wang Zhipeng,Zhu Sha,Zhao Jinge,Nie Ling,Chen Xueqin...&Zeng Hao.(2021).The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer..The Prostate,,
MLA：
Wang Zhipeng,et al."The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.".The Prostate .(2021)
